Cargando…

Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that induce the anti-tumor effects of T cells by targeting co-inhibitory immune checkpoints. The development of ICIs has revolutionized the clinical practice of oncology, leading to significant improvements in outcomes; therefore, ICIs ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, S, Lee, HJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394523/
https://www.ncbi.nlm.nih.gov/pubmed/37376755
http://dx.doi.org/10.4103/jpgm.jpgm_834_22
_version_ 1785083389670326272
author Kang, S
Lee, HJ
Lee, HJ
author_facet Kang, S
Lee, HJ
Lee, HJ
author_sort Kang, S
collection PubMed
description Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that induce the anti-tumor effects of T cells by targeting co-inhibitory immune checkpoints. The development of ICIs has revolutionized the clinical practice of oncology, leading to significant improvements in outcomes; therefore, ICIs are now standard care for various types of solid cancers. Immune-related adverse events, the unique toxicity profiles of ICIs, usually develop 4–12 weeks after initiation of ICI treatment; however, some cases can occur >3 months after cessation of ICI treatment. To date, there have been limited reports about delayed immune-mediated hepatitis (IMH) and histopathologic findings. Herein, we present a case of delayed IMH that occurred 3 months after the last dose of pembrolizumab, including histopathologic findings of the liver. This case suggests that ongoing surveillance for immune-related adverse events is required, even after cessation of ICI treatment.
format Online
Article
Text
id pubmed-10394523
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-103945232023-08-03 Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma Kang, S Lee, HJ Lee, HJ J Postgrad Med ADR Report Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that induce the anti-tumor effects of T cells by targeting co-inhibitory immune checkpoints. The development of ICIs has revolutionized the clinical practice of oncology, leading to significant improvements in outcomes; therefore, ICIs are now standard care for various types of solid cancers. Immune-related adverse events, the unique toxicity profiles of ICIs, usually develop 4–12 weeks after initiation of ICI treatment; however, some cases can occur >3 months after cessation of ICI treatment. To date, there have been limited reports about delayed immune-mediated hepatitis (IMH) and histopathologic findings. Herein, we present a case of delayed IMH that occurred 3 months after the last dose of pembrolizumab, including histopathologic findings of the liver. This case suggests that ongoing surveillance for immune-related adverse events is required, even after cessation of ICI treatment. Wolters Kluwer - Medknow 2023 2023-06-27 /pmc/articles/PMC10394523/ /pubmed/37376755 http://dx.doi.org/10.4103/jpgm.jpgm_834_22 Text en Copyright: © 2023 Journal of Postgraduate Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle ADR Report
Kang, S
Lee, HJ
Lee, HJ
Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma
title Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma
title_full Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma
title_fullStr Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma
title_full_unstemmed Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma
title_short Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma
title_sort delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma
topic ADR Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394523/
https://www.ncbi.nlm.nih.gov/pubmed/37376755
http://dx.doi.org/10.4103/jpgm.jpgm_834_22
work_keys_str_mv AT kangs delayedimmunemediatedhepatitisafterthreecyclesofpembrolizumabforthetreatmentofsinonasalmelanoma
AT leehj delayedimmunemediatedhepatitisafterthreecyclesofpembrolizumabforthetreatmentofsinonasalmelanoma
AT leehj delayedimmunemediatedhepatitisafterthreecyclesofpembrolizumabforthetreatmentofsinonasalmelanoma